{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:12:21Z","timestamp":1780434741490,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Binging Site Group Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The clinical utility of serum immunoglobulin free light chains (sFLC) in IgG4-related disease (IgG4-RD) is unknown. Herein we evaluated their association with clinical phenotypes, serology and activity in patients with IgG4-RD. Cross-sectional study that included 45 patients with IgG4-RD, and as controls 25 with Sj\u00f6gren\u2019s syndrome (SS) and 15 with sarcoidosis. IgG4-RD patients were classified in clinical phenotypes: pancreato-hepato-biliary, retroperitoneum\/aorta, head\/neck-limited and Mikulicz\/systemic; as well as proliferative vs. fibrotic phenotypes. We assessed the IgG4-RD Responder Index (IgG4-RD RI) at recruitment and measured IgG1, IgG4, \u03ba and \u03bb sFLC serum levels by turbidometry. sFLC levels were similar among IgG4-RD, SS and sarcoidosis groups. Regarding the IgG4-RD patients, the mean age was 49\u00a0years, 24 (53.3%) were men and 55.5% had activity. Eight (17.7%) belonged to pancreato-hepato-biliary, 6 (13.3%) to retroperitoneum\/aorta, 14 (31.1%) to head\/neck-limited, 16 (35.5%) to Mikulicz\/systemic phenotypes, whereas 36 (80%) to proliferative and 9 (20%) to fibrotic phenotypes. High \u03ba sFLC, \u03bb sFLC and \u03ba\/\u03bb ratio were present in 29 (64.4%), 13 (28.9%) and 13 (28.9%) of IgG4-RD\u00a0patients, respectively. There were no differences in sFLC among IgG4-RD\u00a0phenotypes. \u03ba sFLC and \u03ba\/\u03bb ratio correlated positively with the number of involved organs and IgG4-RD RI. Patients with renal involvement had higher \u03ba sFLC and \u03bb sFLC. The AUC for \u03ba sFLC and \u03bb sFLC, for renal involvement was 0.78 and 0.72, respectively. Active IgG4-RD had higher levels of \u03ba sFLC and more frequently a high \u03ba\/\u03bb ratio. The AUC for \u03ba sFLC and \u03ba\/\u03bb ratio for predicting active IgG4-RD was 0.67 and 0.70, respectively. sFLC correlated positively with IgG1 and IgG4 levels. sFLC may be useful as a biomarker of disease activity as well as multiorgan and renal involvement. In particular, a high \u03ba\/\u03bb ratio may identify patients with active disease.<\/jats:p>","DOI":"10.1038\/s41598-021-81321-5","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T11:02:54Z","timestamp":1611054174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Serum immunoglobulin free light chains and their association with clinical phenotypes, serology and activity in patients with IgG4-related disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Eduardo","family":"Mart\u00edn-Nares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Saavedra-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reynerio","family":"Fagundo-Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca Estela","family":"Santinelli-N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Romero-Maceda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Calder\u00f3n-Vasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Hernandez-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"issue":"Pt 5","key":"81321_CR1","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1177\/0004563213518758","volume":"51","author":"M Bhole","year":"2014","unstructured":"Bhole, M., Sadler, R. & Ramassamy, K. Serum-free light-chain assay: Clinical utility and limitations. Ann. Clin. Biochem. 51(Pt 5), 528\u2013542 (2014).","journal-title":"Ann. Clin. Biochem."},{"issue":"2","key":"81321_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/leu.2008.307","volume":"23","author":"A Dispenzieri","year":"2009","unstructured":"Dispenzieri, A. et al. International Myeloma Working Group. International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23(2), 215\u2013224 (2009).","journal-title":"Leukemia"},{"key":"81321_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cca.2013.08.018","volume":"427","author":"E Jenner","year":"2014","unstructured":"Jenner, E. Serum free light chains in clinical laboratory diagnostics. Clin. Chim. Acta. 427, 15\u201320 (2014).","journal-title":"Clin. Chim. Acta."},{"issue":"10","key":"81321_CR4","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1093\/rheumatology\/key180","volume":"57","author":"GM Verstappen","year":"2018","unstructured":"Verstappen, G. M. et al. Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sj\u00f6gren\u2019s syndrome. Rheumatology (Oxford) 57(10), 1812\u20131821 (2018).","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"81321_CR5","doi-asserted-by":"publisher","first-page":"e0138753","DOI":"10.1371\/journal.pone.0138753","volume":"10","author":"A Draborg","year":"2015","unstructured":"Draborg, A. et al. Elevated concentrations of serum immunoglobulin free light chains in systemic lupus erythematosus patients in relation to disease activity, inflammatory status, B cell activity and Epstein\u2013Barr virus antibodies. PLoS ONE 10(9), e0138753 (2015).","journal-title":"PLoS ONE"},{"issue":"12","key":"81321_CR6","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1136\/ard.2009.126441","volume":"69","author":"T Kormelink","year":"2010","unstructured":"Kormelink, T. et al. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab treatment correlates with decrease in disease activity. Ann. Rheum. Dis. 69(12), 2137\u20132144 (2010).","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"81321_CR7","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.autrev.2014.07.003","volume":"13","author":"A Lanteri","year":"2014","unstructured":"Lanteri, A. et al. Serum free light chains of immunoglobuins as biomarkers for systemic sclerosis characteristics, activity and severity. Autoimmun. Rev. 13(9), 974\u2013980 (2014).","journal-title":"Autoimmun. Rev."},{"issue":"9976","key":"81321_CR8","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","volume":"385","author":"T Kamisawa","year":"2015","unstructured":"Kamisawa, T., Zen, Y., Pillai, S. & Stone, J. H. IgG4-related disease. Lancet 385(9976), 1460\u20131471 (2015).","journal-title":"Lancet"},{"issue":"1","key":"81321_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1136\/annrheumdis-2014-205233","volume":"74","author":"ZS Wallace","year":"2015","unstructured":"Wallace, Z. S. et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann. Rheum. Dis. 74(1), 190\u2013195 (2015).","journal-title":"Ann. Rheum. Dis."},{"issue":"21","key":"81321_CR10","doi-asserted-by":"publisher","first-page":"e3785","DOI":"10.1097\/MD.0000000000003785","volume":"95","author":"M Hao","year":"2016","unstructured":"Hao, M., Liu, M., Fan, G., Yang, X. & Li, J. Diagnostic value of serum IgG4 for IgG4-related disease: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 95(21), e3785 (2016).","journal-title":"Medicine (Baltimore)."},{"issue":"3","key":"81321_CR11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2018-214603","volume":"78","author":"ZS Wallace","year":"2019","unstructured":"Wallace, Z. S. et al. Clinical phenotypes of IgG4-related disease: An analysis of two international cross-sectional cohorts. Ann. Rheum. Dis. 78(3), 406\u2013412 (2019).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"81321_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1080\/14397595.2019.1572575","volume":"30","author":"E Mart\u00edn-Nares","year":"2020","unstructured":"Mart\u00edn-Nares, E., \u00c1ngeles-\u00c1ngeles, A. & Hernandez-Molina, G. Major salivary gland enlargement in IgG4-related disease is associated with multiorgan involvement and higher basal disease activity. Mod. Rheumatol. 30(1), 172\u2013177 (2020).","journal-title":"Mod. Rheumatol."},{"issue":"4","key":"81321_CR13","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s10067-018-4402-x","volume":"38","author":"J Yoo","year":"2019","unstructured":"Yoo, J. et al. No overlap between IgG4-related disease and microscopic polyangiitis and granulomatosis with polyangiitis despite elevated serum IgG4 at diagnosis: A retrospective monocentric study. Clin. Rheumatol. 38(4), 1147\u20131154 (2019).","journal-title":"Clin. Rheumatol."},{"issue":"8","key":"81321_CR14","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/j.1572-0241.2007.01264.x","volume":"102","author":"A Ghazale","year":"2007","unstructured":"Ghazale, A. et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am. J. Gastroenterol. 102(8), 1646\u20131653 (2007).","journal-title":"Am. J. Gastroenterol."},{"issue":"21","key":"81321_CR15","doi-asserted-by":"publisher","first-page":"e3625","DOI":"10.1097\/MD.0000000000003625","volume":"95","author":"D Gianfreda","year":"2016","unstructured":"Gianfreda, D. et al. Erdheim-Chester disease as a mimic of IgG4-related disease: A case report and a review of a single-center cohort. Medicine (Baltimore). 95(21), e3625 (2016).","journal-title":"Medicine (Baltimore)."},{"issue":"5","key":"81321_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/ajg.2016.40","volume":"111","author":"EL Culver","year":"2016","unstructured":"Culver, E. L. et al. Elevated serum IgG4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective IgG4-related disease UK cohort. Am. J. Gastroenterol. 111(5), 733\u2013743 (2016).","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"81321_CR17","first-page":"157","volume":"112","author":"M Akiyama","year":"2018","unstructured":"Akiyama, M. et al. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sj\u00f6gren\u2019s syndrome adults from a defined population. Clin. Exp. Rheumatol. 112(3), 157\u2013164 (2018).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"9","key":"81321_CR18","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1136\/annrheumdis-2017-212110","volume":"77","author":"M Akiyama","year":"2018","unstructured":"Akiyama, M., Yasuoka, H., Yoshimoto, K. & Takeuchi, T. CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease. Ann. Rheum. Dis. 77(9), 1386\u20131387 (2018).","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"81321_CR19","doi-asserted-by":"publisher","first-page":"R86","DOI":"10.1186\/ar3810","volume":"14","author":"K Kiyama","year":"2012","unstructured":"Kiyama, K. et al. Serum BAFF and APRIL levels in patients with IgG4-related disease and their clinical significance. Arthritis Res. Ther. 14(2), R86 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"81321_CR20","doi-asserted-by":"publisher","first-page":"426759","DOI":"10.1155\/2013\/426759","volume":"2013","author":"A Grados","year":"2013","unstructured":"Grados, A. et al. Serum immunoglobulin free light chain assessment in IgG4-related disease. Int. J. Rheumatol. 2013, 426759 (2013).","journal-title":"Int. J. Rheumatol."},{"issue":"6","key":"81321_CR21","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.2215\/CJN.02290508","volume":"3","author":"CA Hutchison","year":"2008","unstructured":"Hutchison, C. A. et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 3(6), 1684\u20131690 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"81321_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10067-010-1674-1","volume":"30","author":"L Chiche","year":"2011","unstructured":"Chiche, L. et al. Normalization of serum-free light chains in patients with systemic lupus erythematosus upon rituximab treatment and correlation with biological disease activity. Clin. Rheumatol. 30(5), 685\u2013689 (2011).","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"81321_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1309\/AJCP41XCVBHEQCEL","volume":"142","author":"JF Jacobs","year":"2014","unstructured":"Jacobs, J. F., van der Molen, R. G. & Keren, D. F. Relatively restricted migration of polyclonal IgG4 may mimic a monoclonal gammopathy in IgG4-related disease. Am. J. Clin. Pathol. 142(1), 76\u201381 (2014).","journal-title":"Am. J. Clin. Pathol."},{"issue":"3","key":"81321_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/ajcp\/aqw113","volume":"146","author":"WG Finn","year":"2016","unstructured":"Finn, W. G. et al. Detection of polyclonal Increases in immunoglobulin G4 subclass by distinct patterns on capillary serum protein electrophoresis: Diagnostic pitfalls and clinical observations in a study of 303 cases. Am. J. Clin. Pathol. 146(3), 303\u2013311 (2016).","journal-title":"Am. J. Clin. Pathol."},{"issue":"5","key":"81321_CR25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/archophthalmol.2010.45","volume":"128","author":"T Kubota","year":"2010","unstructured":"Kubota, T., Moritani, S., Katayama, M. & Terasaki, H. Ocular adnexal IgG4-related lymphoplasmacytic infiltrative disorder. Arch. Ophthalmol. 128(5), 577\u2013584 (2010).","journal-title":"Arch. Ophthalmol."},{"issue":"2","key":"81321_CR26","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1365-2559.2011.04089.x","volume":"60","author":"H Go","year":"2012","unstructured":"Go, H. et al. Ocular adnexal IgG4-related disease: Comparative analysis with mucosa-associated lymphoid tissue lymphoma and other chronic inflammatory conditions. Histopathology 60(2), 296\u2013312 (2012).","journal-title":"Histopathology"},{"issue":"1","key":"81321_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","volume":"79","author":"ZS Wallace","year":"2020","unstructured":"Wallace, Z. S. et al. The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease. Ann. Rheum. Dis. 79(1), 77\u201387 (2020).","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"81321_CR28","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1002\/art.39205","volume":"67","author":"ZS Wallace","year":"2015","unstructured":"Wallace, Z. S. et al. IgG4-related disease: Clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol. 67(9), 2466\u20132475 (2015).","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"81321_CR29","doi-asserted-by":"publisher","first-page":"6010","DOI":"10.1038\/s41598-020-62941-9","volume":"10","author":"M Umeda","year":"2020","unstructured":"Umeda, M. et al. Thymus and activation-regulated chemokine as a biomarker for IgG4-related disease. Sci. Rep. 10(1), 6010 (2020).","journal-title":"Sci. Rep."},{"issue":"8","key":"81321_CR30","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/blood-2005-07-2922","volume":"107","author":"A Dispenzieri","year":"2006","unstructured":"Dispenzieri, A. et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 107(8), 3378\u20133383 (2006).","journal-title":"Blood"},{"issue":"3","key":"81321_CR31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2141.2007.06561.x","volume":"137","author":"MC Kyrtsonis","year":"2007","unstructured":"Kyrtsonis, M. C. et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br. J. Haematol. 137(3), 240\u2013243 (2007).","journal-title":"Br. J. Haematol."},{"issue":"1","key":"81321_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/s10165-011-0571-z","volume":"22","author":"H Umehara","year":"2012","unstructured":"Umehara, H. et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD). Mod. Rheumatol. 22(1), 21\u201330 (2012).","journal-title":"Mod. Rheumatol."},{"issue":"1","key":"81321_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","volume":"69","author":"CH Shiboski","year":"2017","unstructured":"Shiboski, C. H. et al. 2016 American College of Rheumatology\/European League Against Rheumatism Classification criteria for primary Sj\u00f6gren\u2019s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 69(1), 35\u201345 (2017).","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"81321_CR34","first-page":"149","volume":"16","author":"GW Hunninghake","year":"1999","unstructured":"Hunninghake, G. W. et al. ATS\/ERS\/WASOG statement on sarcoidosis. American Thoracic Society\/European Respiratory Society\/World Association of Sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc. Diffuse Lung Dis. 16(2), 149\u2013173 (1999).","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"81321_CR35","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S2665-9913(19)30017-7","volume":"1","author":"W Zhang","year":"2019","unstructured":"Zhang, W. & Stone, J. H. Management of IgG4-related disease. Lancet Rheumatol. 1, e55\u2013e66 (2019).","journal-title":"Lancet Rheumatol."},{"issue":"11","key":"81321_CR36","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/acr.23543","volume":"70","author":"ZS Wallace","year":"2018","unstructured":"Wallace, Z. S. et al. An international multispecialty validation study of the IgG4-related disease responder index. Arthritis Care Res. (Hoboken). 70(11), 1671\u20131678 (2018).","journal-title":"Arthritis Care Res. (Hoboken)."},{"issue":"9","key":"81321_CR37","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","volume":"48","author":"JA Katzmann","year":"2002","unstructured":"Katzmann, J. A. et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem. 48(9), 1437\u20131444 (2002).","journal-title":"Clin Chem."}],"updated-by":[{"DOI":"10.1038\/s41598-021-91558-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81321-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81321-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81321-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:22:56Z","timestamp":1670034176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81321-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["81321"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-81321-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"20 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-021-91558-9","URL":"https:\/\/doi.org\/10.1038\/s41598-021-91558-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1832"}}